Icon

VIMPAT (nda022253)- (50MG,100MG,150MG,200MG)

LACOSAMIDE UCB INC
50MG,100MG,150MG,200MG
Yes No
2022-Mar-17 Expired
None None
None No
VIMPAT is indicated for: • Treatment of partial-onset seizures in patients 1 month of age and older • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
16 2 12
Total Other Developers 9
Drugs with Suitability No
50MG ** ** Up - 10
100MG ** ** Up - 10
150MG ** ** Up - 10
200MG ** ** Up - 10
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** **** *** * ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ****** ****** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** *** **** *** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** *** **** *** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****, ***, *** ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***/*, ***, ***/*, ***/* & ***/* ******* ****** ***** *****, *******, *****, ***** & *** ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******* ******** ****** *************** ******* *********** **** **. ** *** **, **** ******** ****, ********, *****, ***** *** *** ******, ***** (***) ***
****** ******** ****** *** ****** **** *********** ******* *****, *.*. **********, ****** - *****, *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.